TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28277801
Drug: Licensed Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed Hib vaccine and MenAC vaccine
Study: 12701671
Drug: alprazolam with
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alprazolam with pre-treatment of carbamazepine
Study: 10720509
Drug: Recombinant gp120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant gp120 vaccines (various doses from SF‐2 or MN strains)
Study: 10720509
Drug: Accelerated immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated immunization schedule with lowest dose of SF‐2 vaccine
Study: 8240640
Drug: Flumazenil (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.2 mg initial injection, followed by 0.1 mg per minute until desired vigilance)
Study: 27354081
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin given from 11 to 13 weeks' gestation
Study: 23980355
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy
Study: 28983705
Drug: Quarterly intravenous
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarterly intravenous bisphosphonates (3 mg ibandronate every 3 months)
Study: 28983705
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral bisphosphonates (70 mg alendronate orally once each week for 12 months)
Study: 28983705
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral bisphosphonates (70 mg alendronate)
Study: 23782588
Drug: Tocilizumab 162
Normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 162 mg subcutaneously QW
Study: 16773938
Drug: Immediate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate therapy for patients with moderate or high conversion risk (e.g. elderly age, greater intraocular pressure, central corneal thickness, greater cup/disc ratio)
Study: 8667057
Drug: CCK‐8 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐8 infusion (0.3 ng/kg per min for 60 min)
Study: 8667057
Drug: CCK‐8 bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐8 bolus injection (0.04 microgram/kg)
Study: 1539732
Drug: CCK‐8 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐8 infusion
Study: 8667057
Drug: CCK‐8 bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐8 bolus injection
Study: 8150549
Drug: Cefpirome 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 0.5 g
Study: 1601759
Drug: Cefpirome 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 1.0 g every 12 h for 3.5 days
Study: 1601759
Drug: Cefpirome (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome (all doses)
Study: 9683366
Drug: Simultaneous radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous radiation and chemotherapy (cis-DDP, 5-fluorouracil, leucovorin)
Study: 30901867
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron
Study: 25293524
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg droperidol
Study: 2256469
Drug: Ciclosporin (CS)
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporin (CS) at low doses (not exceeding 5 mg/kg/day)
Study: 19017589
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy
Study: 21392068
Drug: Combined motivational
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined motivational enhancement and cognitive behaviour therapy
Study: 20307457
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection to heel
Study: 11512649
Drug: Alfentanil 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 10 microg x kg(‐1) and suxamethonium 1 mg x kg(‐1)
Study: 17823012
Drug: Periarticular injections
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injections
Study: 15183925
Drug: Caffeine and
Normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine and glucose drink (68 g carbohydrate and 38 mg caffeine)
Study: 15183925
Drug: Caffeine and
Normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine and glucose drink (68 g carbohydrate and 46 mg caffeine)
Study: 31116468
Drug: Various treatments/interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments/interventions in physiological research studies
Study: 26001567
Drug: Rivastigmine 0mg
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine 0mg twice a day
Study: 26001567
Drug: Rivastigmine 1.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 1.5mg twice a day
Study: 26001567
Drug: Rivastigmine 3mg
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine 3mg twice a day
Study: 15315849
Drug: Duplex vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duplex vaccine
Study: 15315849
Drug: diTeBooster vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diTeBooster vaccine
Study: 9311648
Drug: Artesunate suppositories
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate suppositories (200 mg/capsule) given rectally at 0, 4, 8, 12, 24, 36, 48, and 60 hr (total = 1,600 mg) followed by oral mefloquine (750 mg at 72 hr and 500 mg at 84 hr)
Study: 9311648
Drug: Artesunate suppositories
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate suppositories (200 mg/capsule) given rectally at 0, 12, 24, 36, 48, and 60 hr (total = 1,200 mg) followed by oral mefloquine (750 mg at 72 hr and 500 mg at 84 hr)
Study: 8110401
Drug: Rice-based solution
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-based solution without electrolytes (Group A)
Study: 8110401
Drug: Rice-based solution
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-based solution with electrolytes (Group B)
Study: 2437278
Drug: High-dose gammaglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose gammaglobulin 400 mg/kg/d for 3 days plus aspirin 30 mg/kg/d
Study: 2437278
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone at the same dosage (30 mg/kg/d)
Study: 25636858
Drug: Target Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target Inhalation Mode (TIM)
Study: 26669827
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 77 mg of A1-PI
Study: 791333
Drug: Labetalol 1.0‐2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 1.0‐2.0 mg/kg intravenously
Study: 6519163
Drug: Propranolol 10
Normalized name: propranolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 10 mg intravenously
Study: 30952158
Drug: Chloroquine (25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25mg base/kg) plus primaquine (1 mg/kg/day for 7 days)
Study: 30952158
Drug: Dihydroartemisinin-piperaquine (dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine (0.5 mg/kg/day for 14 days)
Study: 30952158
Drug: 14-day high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day high-dose primaquine regimen
Study: 30952158
Drug: 7-day high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day high-dose primaquine regimen
Study: 28938439
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg metformin with cholecystokinin (0.4 pmol × kg‐1 × min‐1)
Study: 28938439
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg metformin without cholecystokinin
Study: 22404879
Drug: Mindfulness-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based therapy (MBT) consisting of eight 1-hour sessions over 4 weeks
Study: 17442602
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine (10mg)
Study: 15007518
Drug: Cognitive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive group therapy
Study: 9257749
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg intravenously twice a day for 4 days and Sucralfate 2 g orally three times a day for 7 days (Group A)
Study: 8292694
Drug: No neuroendocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neuroendocrine tests administered
Study: 3802690
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release oral morphine sulphate (MS-Contin)
Study: 3802690
Drug: Solution of
Normalized name: Solution of protein-free hemodialysate of calf blood
DrugBank: SM-1997 (DB18670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution of oral morphine sulphate
Study: 30595364
Drug: Melatonin 25
Normalized name: calcium phosphate/melatonin 250 mg-1.5 mg ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 25 mg/d for 6 months
Study: 26498427
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml 0.4% CHO ingested serially via 25 ml boluses
Study: 26498427
Drug: 375 ml
Normalized name: isopropyl alcohol 0.0375 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 ml 0% CHO control (CON) ingested followed by one 25 ml 6% CHO mouth rinse
Study: 31987231
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg)
Study: 23657486
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (50 mg)
Study: 22407780
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of curcumin and diclofenac sodium
Study: 15992643
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day simvastatin (aggressive therapy)
Study: 15992643
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (20 mg and 80 mg simvastatin)
Study: 15992643
Drug: Patients reaching
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients reaching mean on-treatment LDL-C < or = 100 mg/dl
Study: 2185822
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg
Study: 2185822
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg
Study: 18978102
Drug: Mifepristone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 10 mg
Study: 1986952
Drug: Luteal support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal support therapy (intramuscular injections of progesterone and/or human chorionic gonadotropin)
Study: 3916369
Drug: Pentaerythritol tetranicotinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerythritol tetranicotinate (Perycit) 750 mg daily
Study: 23166343
Drug: Continuous-infusion doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion doxorubicin (360 mg/m2 in 30 mg/m2 doses every 3 weeks over 48 hours)
Study: 23166343
Drug: Bolus-infusion doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus-infusion doxorubicin (360 mg/m2 in 30 mg/m2 doses every 3 weeks within 15 minutes)
Study: 8450994
Drug: Azathioprine 2
Normalized name: azathioprine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 2 to 2.5 mg/kg/d
Study: 3708119
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg furosemide tablet (Product 1)
Study: 3708119
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg furosemide tablet (Product 2)
Study: 27687681
Drug: Constant dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant dose, 4500 SW at 20 kV
Study: 27687681
Drug: Dose reduction,
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction, 1500 SW at 22 kV, followed by 1500 SW at 20 kV and then 1500 SW at 18 kV
Study: 26117944
Drug: Qilin Pills
Normalized name: Qilib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilin Pills (6 g, bid)
Study: 26117944
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg, qd)
Study: 26117944
Drug: Qilin Pills
Normalized name: Qilib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilin Pills plus sertraline
Study: 24620654
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined radiotherapy (34 patients)
Study: 24620654
Drug: Chemotherapy (23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (23 patients)
Study: 21455074
Drug: Neostigmine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine group (neostigmine 20 μg kg‐1)
Study: 19878605
Drug: Conventional time-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional time-based Green Prescription
Study: 16483622
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (10 consecutive daily i.v. injections of 2.16 mg/kg)
Study: 16483622
Drug: Regimen C
Normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C (graded dosing: 1.8, 2.16, 2.52, 2.52, 2.88, 3.24, then 3.6 mg/kg for the last three injections)
Study: 10839903
Drug: 2.5 microg
Normalized name: Digoxin 62.5 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 microg sufentanil combined with 2.5 mg bupivacaine
Study: 10839903
Drug: 5.0 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 microg sufentanil combined with 2.5 mg bupivacaine
Study: 10839903
Drug: 10.0 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 microg sufentanil combined with 2.5 mg bupivacaine
Study: 10839903
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 microg sufentanil combined with 2.5 mg bupivacaine)
Study: 9352866
Drug: Isosorbide-5-mononitrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (20 mg three times daily)
Study: 25429853
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg
Study: 11570381
Drug: Maze procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maze procedure with SICTRA (20 to 32 W; 200 to 320 mL/h saline)
Study: 9551875
Drug: Irbesartan 75
Normalized name: irbesartan 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 75 mg once daily
Study: 4026908
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg once daily
Study: 7941939
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine 0.5% 2.5 mg kg‐1
Study: 2896555
Drug: ICI 118,551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551 10 mg
Study: 2896555
Drug: ICI 118,551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551 100 mg
Study: 27382814
Drug: Pentazocine with
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentazocine with rectal diclofenac (100mg diclofenac suppository and 30mg intramuscular pentazocine)
Study: 27382814
Drug: Pentazocine alone
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentazocine alone (30mg intramuscular pentazocine)
Study: 16368878
Drug: Effective antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective antiretroviral therapy (ART)
Study: 21797916
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal gel and placebo pills
Study: 12169076
Drug: Hand-rubbing protocol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand-rubbing protocol with 75% aqueous alcoholic solution containing propanol‐1, propanol‐2, and mecetronium etilsulfate
Study: 12169076
Drug: Hand-scrubbing protocol
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand-scrubbing protocol with antiseptic preparation containing 4% povidone iodine or 4% chlorhexidine gluconate
Study: 3279748
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (10 mg/d)
Study: 20960028
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day, Schedule 2/1) + Pemetrexed (500 mg/m2)
Study: 20960028
Drug: Sunitinib (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (37.5 mg/day, continuous daily dosing) + Pemetrexed (500 mg/m2)
Study: 17490489
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg once daily for 12 weeks
Study: 17490489
Drug: Bendroflumethiazide 2.5
Normalized name: bendroflumethiazide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide 2.5 mg once daily for 12 weeks
Study: 15658072
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of intranasal butorphanol (treatment B)
Study: 15658072
Drug: Intranasal butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal butorphanol (1 mg and 2 mg)
Study: 15658072
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (1 mg, 2 mg intranasal, and 2 mg i.v.)
Study: 11055460
Drug: Methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.3 mg/kg per dose)
Study: 8398318
Drug: Infusional FEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusional FEC (5‐fluorouracil 200 mg/m2 i.v. 24 hourly by continuous infusion for 6 months, epirubicin 50 mg/m2 i.v. bolus once every 3 weeks for 6 months, cisplatin 60 mg/m2 i.v. once every 3 weeks for 6 months)
Study: 3131943
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg mitomycin C (MMC) instilled for 0.5 hours
Study: 3131943
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg mitomycin C (MMC) instilled for 1.0 hours
Study: 3131943
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg mitomycin C (MMC) instilled for both 0.5 and 1.0 hours
Study: 29136032
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with VL 1,000-5,000 copies/ml
Study: 17961560
Drug: 100 microg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg/day E(2) patch, oral medroxyprogesterone acetate 10 mg for 12 days each month for patients
Study: 10908898
Drug: Levetiracetam 1000
Normalized name: levetiracetam 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 1000 mg/day
Study: 17129331
Drug: Nurse practitioners
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse practitioners (NPs) as consultants performing basic incontinence evaluation and treatment for 16 weeks
Study: 17129331
Drug: Nurse practitioners
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse practitioners (NPs) as consultants performing basic incontinence evaluation and treatment
Study: 9062610
Drug: metoclopramide 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 0.15 mg/kg
Study: 16178945
Drug: Sumatriptan 50
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 50 mg
Study: 20608995
Drug: Rosuvastatin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin at 2.5 mg/day (ROSUVA, n = 11)
Study: 16569825
Drug: Gatifloxacin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin monotherapy
Study: 11207516
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (400 mg), clarithromycin (250 mg), metronidazole (400 mg) given twice daily for 1 week
Study: 11207516
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg), clarithromycin (250 mg), metronidazole (400 mg) given twice daily for 1 week
Study: 9049575
Drug: Sufentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil infusion at 30 micrograms.kg‐1.min‐1 (group I)
Study: 9049575
Drug: Sufentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil infusion at 5 micrograms.kg‐1.min‐1 (group II)
Study: 2873396
Drug: Cyclosporin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin 7.5 mg/kg per day
Study: 31910992
Drug: Lower target
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower target glycemic control (80-100 mg/dL)
Study: 31910992
Drug: Higher target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher target glycemic control (150-180 mg/dL)
Study: 19176440
Drug: Symptom-guided therapy
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-guided therapy
Study: 21959480
Drug: Acetaminophen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (40 mg/kg) plus diclofenac (1 mg/kg)
Study: 18240925
Drug: Spinal cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal cord stimulation (SCS) + physical therapy (PT)
Study: 22502793
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) alone
Study: 17361530
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia with combination of acupuncture (HANS) and enflurane
Study: 31430830
Drug: Single-session Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session Acceptance and Commitment Therapy (ACT) intervention